The risk of rapid prostate specific antigen increase in men with baseline prostate specific antigen 2.0 ng/ml or less

Journal of Urology

Volumn 171, Issue 2 I, 2004, Pages 656-660

  Ito, Kazuto ^a   Yamamoto, Takumi ^a   Suzuki, Kazuhiro ^a   Kurokawa, Kohei ^a   Yamanaka, Hidetoshi ^a  

^a GUNMA UNIVERSITY   (Japan)

Author keywords

Mass screening; Prostate; Prostate specific antigen; Prostatic neoplasms

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER SCREENING; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; SENSITIVITY AND SPECIFICITY; VALIDATION PROCESS;

EID: 0347129593     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ju.0000100109.23348.6b     Document Type: Article

References (10)

1. Prorok, P. C., Andriole, G. L., Bresalier, R. S., Buys, S. S., Chia, D., Crawford, E. D. et al: Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Control Clin Trials, suppl., 21: 273S, 2000
2. Schroder, F. H., Kranse, R., Rietbergen, J., Hoedemaeke, R. and Kirkels, W.: The European Randomized Study of Screening for Prostate Cancer (ERSPC): an update. Members of the ERSPC, Section Rotterdam. Eur Urol, 35: 539, 1999
3. Standaert, B. and Denis L.: The European Randomized Study of Screening for Prostate Cancer: an update. Cancer, 80: 1830, 1997
4. Ito, K., Kubota, Y., Yamamoto, T., Suzuki, K., Fukabori, Y., Kurokawa, K. et al: Long term follow-up of mass screening for prostate carcinoma in men with initial prostate-specific antigen levels of 4.0 ng/ml or less. Cancer, 91: 744, 2001
5. Crawford, D., Chia, D., Andriole, G. L., Reding, D., Gelmann, E. P., Gohagan, J. K. et al: PSA testing interval, reduction in screening intervals: data from the prostate, lung, colorectal and ovarian cancer (PLCO) screening trial. J Urol, suppl., 167: 99, abstract 397, 2002
6. Ito, K., Yamamoto, T., Ohi, M., Takechi, H., Kurokawa, K., Suzuki, K. et al: Natural history of PSA increase with and without prostate cancer. Urology, 62: 64, 2003
7. Pearson, J. D. and Carter, H. B.: Natural history of changes in prostate specific antigen in early stage prostate cancer. J Urol, 152: 1743, 1994
8. Smith, D. S., Catalona, W. J. and Herschman, J. D.: Longitudinal screening for prostate cancer with prostate-specific antigen. JAMA, 276: 1309, 1996
9. de Koning, H. J., Auvinen, A., Berenguer Sanchez, A., Calais da Silva, F., Ciatto, S., Denis, L. et al: Large-scale randomized prostate cancer screening trials: program performances in the European Randomized Screening for Prostate Cancer trial and the Prostate, Lung, Colorectal and Ovary cancer trial. Int J Cancer, 97: 237, 2002
10. Ito, K., Kubota, Y., Banzai, R., Yuasa, H., Shimizu, N., Kurokawa, K. et al: The present status, problems, and future of mass screening for prostate cancer in Gunma Prefecture. The report of mass screening for prostate cancer study meeting in 1998. Kitakanto Med J, 49: 81, 1999